您的位置:PharmaNews 研发动态 正文
内容搜索
热门内容
推荐内容
最新内容
反馈意见和建议

Abraxis BioScience and Specialised Therapeutics Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in New Zealand(4)
本文章共5793字,分4页,当前第4页,快速翻页:

The information contained in this press release is as of the date of this release. Abraxis assumes no obligations to update any forward-looking statements contained in this press release as the result of new information or future events or developments.

Contact: Investor and Media Inquiries
Pondel Wilkinson Inc.
Rob Whetstone
310-279-5963
or
Monsoon Communications
Emma Powers
Level 1 350 Collins Street
Melbourne VIC 3000
Ph: +613 9620 3333
www.monsoon.com.au

 

转载自pharmaLive


 

 

点这里复制本页地址     发送给您QQ/MSN上的好友


相关文章

  Abbott's Simcor ( niacin extended-releas

  FDA Approves Drug for Chronic Drooling i

  Quintiles Announces New European Headqua

  Covance Reports Second Quarter Revenue o

  Commonwealth Biotechnologies, Inc. Provi

Shionogi Inc. Announces FDA Approval of

Researchers Solve Mystery of Uner Tan Sy

WaferGen Announces Purchase of SmartChip

Plant Compound Resveratrol Shown to Supp

New pathway to Parkinson's and Alzheimer

deCODE Shows how Genetic Risk of Kidney

Bionovo to Advance Menerba to Phase 3 Cl

Geron to Proceed with First Human Clinic

Orexigen Therapeutics Announces Publicat

Basilea Pharmaceutica AG (CH) - Data on

相关评论

    
本文章所属分类:首页 研发动态